Close Menu

'Buyer Beware?'

The Motley Fool's Brian Orelli this week calls genome sequencing "the world's best innovation that isn't worth investing in." Orelli says that he sees "little reason to invest in the genome sequencing industry," particularly because "what's great for the end users isn't necessarily great for those producing the tools."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.